P Lyn

721 total citations
7 papers, 542 citations indexed

About

P Lyn is a scholar working on Surgery, Neurology and Molecular Biology. According to data from OpenAlex, P Lyn has authored 7 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 5 papers in Neurology and 4 papers in Molecular Biology. Recurrent topics in P Lyn's work include Testicular diseases and treatments (6 papers), Neuroblastoma Research and Treatments (5 papers) and Cancer therapeutics and mechanisms (3 papers). P Lyn is often cited by papers focused on Testicular diseases and treatments (6 papers), Neuroblastoma Research and Treatments (5 papers) and Cancer therapeutics and mechanisms (3 papers). P Lyn collaborates with scholars based in United States. P Lyn's co-authors include Robert J. Motzer, George J. Bosl, Dean F. Bajorin, Vaia Vlamis, Madhu Mazumdar, P Fischer, Subhash C. Gulati, Howard I. Scher, Lawrence H. Schwartz and Madhu Mazumdar and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

P Lyn

7 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P Lyn United States	7	406	204	163	127	123	7	542
S. Weinknecht Germany	11	414 1.0×	100 0.5×	116 0.7×	88 0.7×	35 0.3×	14	546
Mario Ghosn France	10	150 0.4×	64 0.3×	55 0.3×	34 0.3×	29 0.2×	39	305
C Théodore France	11	178 0.4×	81 0.4×	77 0.5×	33 0.3×	16 0.1×	28	353
D. S. Verma United States	9	63 0.2×	76 0.4×	82 0.5×	15 0.1×	265 2.2×	13	450
H D Homesley United States	9	335 0.8×	30 0.1×	58 0.4×	468 3.7×	10 0.1×	12	611
L Vellekoop United States	10	52 0.1×	66 0.3×	67 0.4×	9 0.1×	307 2.5×	17	452
Shigeo Nakamura Japan	9	104 0.3×	88 0.4×	29 0.2×	22 0.2×	15 0.1×	12	437
Maria Grazia Cantù Italy	9	223 0.5×	22 0.1×	69 0.4×	437 3.4×	10 0.1×	16	574
Pascale Halle France	11	51 0.1×	101 0.5×	56 0.3×	9 0.1×	257 2.1×	20	413
Maria Carolina Gelli Italy	11	146 0.4×	49 0.2×	54 0.3×	31 0.2×	8 0.1×	32	371

Countries citing papers authored by P Lyn

Since Specialization

Citations

This map shows the geographic impact of P Lyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Lyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Lyn more than expected).

Fields of papers citing papers by P Lyn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Lyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Lyn. The network helps show where P Lyn may publish in the future.

Co-authorship network of co-authors of P Lyn

This figure shows the co-authorship network connecting the top 25 collaborators of P Lyn. A scholar is included among the top collaborators of P Lyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P Lyn. P Lyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Motzer, Robert J., Madhu Mazumdar, Dean F. Bajorin, et al.. (1997). High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.. Journal of Clinical Oncology. 15(7). 2546–2552. 112 indexed citations

2.

Motzer, Robert J., Joel Sheinfeld, Madhu Mazumdar, et al.. (1995). Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.. Journal of Clinical Oncology. 13(11). 2700–2704. 49 indexed citations

3.

Motzer, Robert J., P Lyn, P Fischer, et al.. (1995). Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.. Journal of Clinical Oncology. 13(8). 1958–1965. 66 indexed citations

4.

Moasser, Mark M., Robert J. Motzer, P Lyn, et al.. (1995). all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer. 76(4). 680–686. 25 indexed citations

5.

Motzer, Robert J., Dean F. Bajorin, Lawrence H. Schwartz, et al.. (1994). Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.. Journal of Clinical Oncology. 12(11). 2277–2283. 141 indexed citations

6.

Motzer, Robert J., Madhu Mazumdar, Subhash C. Gulati, et al.. (1993). Phase II Trial of High-Dose Carboplatin and Etoposide With Autologous Bone Marrow Transplantation in First-Line Therapy for Patients With Poor-Risk Germ Cell Tumors. JNCI Journal of the National Cancer Institute. 85(22). 1828–1835. 112 indexed citations

7.

Motzer, Robert J., Subhash C. Gulati, W P Tong, et al.. (1993). Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.. PubMed. 53(16). 3730–5. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact